CJC-1295: Complete Research Guide

Quick answer: CJC 1295 in preclinical research

CJC 1295 is a modified 29-amino acid peptide derivative of growth hormone-releasing hormone (GHRH) designed to stimulate somatotroph cells in the anterior pituitary gland. Preclinical models evaluate its ability to elevate growth hormone (GH) secretion and trigger downstream insulin-like growth factor 1 (IGF-1) transcription in hepatic tissues.

The peptide exists in two distinct primary variants: modified GRF 1-29 (commonly referred to as CJC 1295 without DAC) and CJC 1295 with DAC (Drug Affinity Complex). While modified GRF 1-29 maintains a biological half-life of approximately 30 minutes to preserve natural pulsatile GH release, the DAC addition covalently binds serum albumin to extend plasma half-life to several days.

When sourcing this compound for analytical or cellular research, investigators require verified purity (>98.0% via HPLC), clear mass spectrum sequence confirmation, and low endotoxin levels (<0.01 EU/mg) to prevent cellular toxicity in sensitive assays. High-purity compounds are available for order directly through PX1 Research product catalog.

What is CJC 1295? Structural chemistry and classification

CJC 1295 is classified structurally as a synthetic analog of human growth hormone-releasing hormone (GHRH 1-29). Endogenous human GHRH consists of a 44-amino acid peptide chain, but biological activity is fully retained within the first 29 amino acids (known as Sermorelin or GRF 1-29). Native GRF 1-29 is rapidly degraded in vivo by dipeptidyl peptidase IV (DPP-IV) and enzymatic cleavage, yielding a biological half-life of under 10 minutes.

To enhance metabolic stability and enzymatic resistance, researchers synthesized modified GRF 1-29 by substituting four specific amino acids: D-Alanine at position 2, Glutamine at position 8, Alanine at position 15, and Leucine at position 27. This tetra-substituted structure is what is most commonly denominated as CJC 1295 without DAC.

These strategic amino acid substitutions protect the peptide backbone from rapid DPP-IV cleavage without altering its binding affinity for the GHRH receptor (GHRHR). As a result, the peptide serves as a stable, selective tool for probing the hypothalamic-pituitary-somatotropic axis in controlled laboratory environments.

CJC 1295 DAC vs. CJC 1295 No DAC: Pharmacokinetic comparison

The defining distinction in CJC 1295 research lies between formulations utilizing the Drug Affinity Complex (DAC) and those without it. Understanding the pharmacokinetic variance between these two constructs is vital for designing valid experimental protocols.

CJC 1295 with DAC incorporates a maleimidopropionic acid derivative attached via a lysine linker at the C-terminus. In biological fluids, this maleimide group reacts rapidly and specifically with free thiols, forming a covalent bond with circulating serum albumin. Because albumin has a prolonged elimination half-life in mammalian circulation, the bound CJC 1295 DAC exhibits an extended half-life ranging from 6 to 8 days.

Conversely, CJC 1295 without DAC (modified GRF 1-29) does not bind serum albumin. It exhibits a rapid distribution and elimination phase with a biological half-life of approximately 30 minutes. Researchers selecting between these molecules must weigh the benefits of continuous receptor activation (with DAC) against the physiological simulation of natural, pulsatile GH release (without DAC).

What is the mechanism of action of CJC 1295?

CJC 1295 functions as a selective agonist at the growth hormone-releasing hormone receptor (GHRHR), a class B G-protein-coupled receptor predominantly expressed on somatotroph cells in the anterior pituitary gland. Upon binding, the peptide initiates a conformational change that activates the intracellular G_s alpha subunit.

This activation stimulates adenylate cyclase, leading to an intracellular rise in cyclic adenosine monophosphate (cAMP). Elevated cAMP activates protein kinase A (PKA), which phosphorylates specific voltage-gated calcium channels. The influx of extracellular calcium ions triggers the exocytosis of pre-stored growth hormone secretory vesicles into the intercellular space.

Additionally, sustained signaling through the cAMP/PKA pathway leads to the phosphorylation of cAMP response element-binding protein (CREB), which upregulates GH gene transcription. Through these pathways, CJC 1295 effectively stimulates both immediate GH secretion and ongoing gene transcription without disrupting baseline pituitary autoregulation in cell models.

IGF-1 research and downstream cellular signaling

A primary objective of CJC 1295 research is tracking downstream endocrine cascades, specifically the systemic elevation of insulin-like growth factor 1 (IGF-1). Secreted growth hormone travels through the bloodstream to target tissue receptors, primarily in hepatocytes within the liver.

GH binding to hepatic growth hormone receptors (GHR) activates the JAK2/STAT5b signaling pathway. Phosphorylated STAT5b translocates to the cell nucleus, where it drives the transcription of the IGF-1 gene alongside key binding proteins like IGFBP-3 and ALS (acid-labile subunit).

In vitro and animal models show that sustained elevation of IGF-1 exerts profound effects on tissue repair parameters. Researchers monitor IGF-1 induction when studying collagen synthesis, osteoblast proliferation, cellular hypertrophy, and nitrogen retention in skeletal muscle cultures. For detailed study protocols and related data, explore our dedicated peptide research library.

Synergistic research models: Pairing GHRH with GHRPs

In physiological systems, growth hormone release is regulated by two distinct pathways: GHRH stimulation and ghrelin/growth hormone secretagogue receptor (GHSR) activation. Consequently, preclinical literature heavily emphasizes dual-agonist co-administration models to achieve maximal secretagogue response.

Combining CJC 1295 with a selective GHSR agonist, such as Ipamorelin or GHRP-2, produces a distinct synergistic elevation in growth hormone levels. While CJC 1295 increases cAMP levels via GHRHR, ghrelin mimetics act through the GHSR-1a receptor to elevate intracellular inositol trisphosphate (IP3) and diacylglycerol (DAG), triggering intracellular calcium release.

This dual pathway activation results in a multiplicative, rather than additive, release of GH from anterior pituitary somatotrophs while minimizing baseline somatostatin inhibition. Comparative trials also frequently reference Tesamorelin when mapping differential GHRH peptide potencies in lipid metabolic studies.

Key metrics for evaluating research-grade CJC 1295

To ensure precise baseline consistency across research trials, laboratory personnel should evaluate potential peptide lots against strict analytical criteria before procurement. The following standardized criteria provide a framework for vetting research materials:

Purity Verification: Must be confirmed equal to or exceeding 98.0% via High-Performance Liquid Chromatography (HPLC) with single-peak clarity.

Sequence Identity: Absolute molecular mass identification verified by Liquid Chromatography-Mass Spectrometry (LC-MS) matching the precise theoretical molecular weight.

Endotoxin Quantitation: Verified low endotoxin content (<0.01 EU/mg) assessed via Limulus Amebocyte Lysate (LAL) testing to prevent cell culture inflammation or artifactual cell death.

Residual Solvents: Complete removal of trifluoroacetic acid (TFA) salts and organic synthesis solvents below standard analytical thresholds.

Solubilization Standards: Freeze-dried lyophilisate must dissolve completely in sterile reconstitution media without aggregation, cloudiness, or particulate suspension.

Lot Traceability: Every vial must trace back to a specific, published Certificate of Analysis (COA) matching the exact production lot.

How to vet a supplier: Commercial red flags

The research peptide market contains significant variation in chemical quality, analytical transparency, and cold-chain management. Identifying low-quality vendors requires recognizing common operational red flags during procurement evaluation.

A primary red flag is the reliance on generic or outdated Certificates of Analysis. Vendors that publish a single, static COA across multiple product batches fail to ensure lot-to-lot consistency. Each batch of CJC 1295 vials must possess a distinct COA corresponding directly to the batch number printed on the container label.

Second, beware of suppliers that omit Mass Spectrometry (MS) data or only provide partial HPLC chromatograms without clear integration tables. Without full MS spectra, mass accuracy and sequence identity remain unverified. Finally, suppliers operating without verifiable US synthesis or domestic dispatch centers present increased risk of temperature degradation and customs seizure during transit.

Analytical testing: HPLC, Mass Spectrometry, and Endotoxin assays

At PX1 Research, quality assurance relies on rigorous, independent analytical testing executed on every synthesized lot prior to catalog distribution.

High-Performance Liquid Chromatography (HPLC) measures chemical purity by separating the target peptide from synthesis byproducts, truncated sequences, and oxidation products. Research-grade CJC 1295 must display a sharp primary peak representing >98.0% total area integration.

Electrospray Ionization Mass Spectrometry (ESI-MS) confirms the exact molecular mass of the peptide chain. For CJC 1295 without DAC (modified GRF 1-29), the theoretical monoisotopic mass of 3357.88 Da must be verified within tight mass tolerance. Lastly, endotoxin testing via LAL assay guarantees that bacterial lipopolysaccharides do not contaminate the lyophilisate, ensuring safety across delicate cell and animal models.

Handling, reconstitution, and stability parameters in the lab

Lyophilized CJC 1295 maintains long-term structural stability when stored at -20°C to -80°C in a desiccated environment. Exposure to ambient moisture, room temperatures, or UV light can induce peptide oxidation and cleavage over extended periods.

For laboratory reconstitution, researchers typically introduce sterile Bacteriostatic Water (containing 0.9% benzyl alcohol) or sterile physiological saline. The solvent should be directed gently against the inner glass wall of the vial rather than sprayed directly onto the lyophilized cake to avoid shearing delicate peptide bonds.

Once reconstituted into solution, CJC 1295 should be maintained at 2°C to 8°C and utilized within target research timelines. Avoid repeated freeze-thaw cycles, as ice crystal formation can denature the tertiary peptide structure and lead to aggregation.

Ordering CJC 1295 from PX1 Research

PX1 Research delivers verified, high-purity peptides engineered specifically for demanding in vitro and preclinical research applications. When you select PX1 Research for your laboratory needs, you receive fully characterized reagents backed by rigorous quality controls.

Every order of CJC 1295 ships in secure, vacuum-sealed glass vials engineered to maintain lyophilisate integrity. Orders placed before 3 PM EST Monday through Friday dispatch same-day from our dual logistics hubs in California and Arizona, providing rapid, fully tracked domestic transit to minimize environmental exposure.

Each shipment includes immediate digital access to batch-specific COAs, featuring raw HPLC chromatograms, mass spectra, and endotoxin assay results. To equip your facility with fully verified GHRH analogs, order 10 mg vials of CJC 1295 directly from our catalog, browse our complete selection of research peptides, or apply for custom institutional volume pricing through our wholesale portal.